SCHEMBL14475243

SCHEMBL14475243

COc1cc(-c2ccc(F)c(F)c2)cc2c(N3CC(F)(F)C3)nc(-c3cccnc3)nc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ GAA P10253 1/20 0.43
▸ CHRNB2 P17787 1/20 0.40
▸ CHRNA5 P30532 1/20 0.40
▸ CHRNA4 P43681 1/20 0.40
▸ PDE2A O00408 4/20 0.39
▸ PDE10A Q9Y233 4/20 0.39
▸ PDE5A O76074 3/20 0.39
▸ PDE11A Q9HCR9 3/20 0.39
▸ NPC1 O15118 3/20 0.38
▸ RAB9A P51151 2/20 0.38
▸ TTK P33981 1/20 0.38
▸ PDE4A P27815 1/20 0.38
▸ ABCB1 P08183 4/20 0.37
▸ ABCC1 P33527 3/20 0.37
▸ LMNA P02545 2/20 0.37
▸ SMN1; SMN2 Q16637 2/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ BACE1 P56817 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16184739 0.91 MAPT (0.44) MAPTALDH1A1GAAPDE2APDE10A
SCHEMBL16184721 0.90 MAPT (0.43) MAPTALDH1A1GAAPDE2APDE10A
SCHEMBL16184803 0.90 MAPT (0.44) MAPTALDH1A1GAAPDE2APDE10A
SCHEMBL16184051 0.89 MAPT (0.46) MAPTALDH1A1GAACHRNB2CHRNA5
SCHEMBL14475253 0.89 MAPT (0.48) MAPTALDH1A1GAACHRNB2CHRNA5
SCHEMBL16184810 0.88 MAPT (0.50) MAPTALDH1A1GAACHRNB2CHRNA5
SCHEMBL16184786 0.88 BACE1 (0.43) MAPTALDH1A1GAAPDE2APDE10A
SCHEMBL16184707 0.88 MAPT (0.45) MAPTALDH1A1GAAPDE2APDE10A
SCHEMBL16184813 0.88 CYP1A2 (0.52) MAPTALDH1A1GAACHRNB2CHRNA5
SCHEMBL14475241 0.87 MAPT (0.42) MAPTALDH1A1GAACHRNB2CHRNA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed
WO-2013003586-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-01-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE PPP2CA, PPP4C, PPP3CB MAPT 509/4885ALDH1A1 1687/4885GAA 406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback